Pepinemab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pepinemab
DrugBank Accession Number
DB15155
Background

Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).

Type
Biotech
Groups
Investigational
Synonyms
  • MOAB VX15/2503
  • Pepinemab
  • VX15/2503

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
BPZ4A29SYE
CAS number
2097151-87-4

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHuntington's Disease (HD)1
1CompletedTreatmentMultiple Sclerosis1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentPathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
1RecruitingTreatmentSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
1, 2Active Not RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm / Refractory Osteosarcoma1
1, 2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2Not Yet RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm1
1, 2RecruitingTreatmentAlzheimer's Disease (AD)1
1, 2RecruitingTreatmentMetastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:54 / Updated on February 21, 2021 18:55